Edgewise Therapeutics Announces Expansion Of Their EDG-5506 Clinical Program In Duchenne Muscular Dystrophy
Portfolio Pulse from Benzinga Newsdesk
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) has announced the expansion of their clinical development program of EDG-5506, a drug designed to prevent muscle damage in dystrophinopathies, including Duchenne. The company is initiating a new Phase 2 trial (FOX) for boys with Duchenne who have been previously treated with gene therapy. They are also continuing dose escalation and expanding enrollment in their Phase 2 LYNX trial. The company expects to report Phase 2 interim data in the first half of 2024, with the Phase 3 dose identified.
October 26, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edgewise Therapeutics is expanding its clinical trials for EDG-5506, a drug for Duchenne muscular dystrophy. This could potentially lead to a new treatment option for Duchenne patients, which would be a significant development for the company.
The expansion of the clinical trials for EDG-5506 indicates that the company is making progress in its development. If successful, this could lead to a new treatment option for Duchenne muscular dystrophy, which would be a significant development for the company and could potentially boost its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100